Hormone-modulating therapy decreased risk of dementia in breast cancer patients
1. In a retrospective cohort study of women newly diagnosed with breast cancer, use of hormone...
Read More
Oncology
#VisualAbstract: Irinotecan and Temozolomide Plus Dasatinib and Rapamycin Improved Progression-Free Survival for Relapsed or Refrcatory Neuroblastoma
Click here to read this study in Lancet Oncology. ©2024 2 Minute Medicine, Inc. All rights...
Read More
Vimseltinib may be promising in treating symptomatic tenosynovial giant cell tumour
1. Tumor response rate at 25 weeks was significantly greater in vimseltinib than placebo. 2. Most...
Read More
Multi-Organ Immune-related Adverse Events from Immune Checkpoint Inhibitors
1. Co-occurrences could be clustered together into 7 clusters based on the predominant organ...
Read More
Tisotumab Vedotin as Second or Third-Line Therapy for Recurrent Cervical Cancer
1. Median overall survival was 11.5 months in the tisotumab vedotin group and 9.5 months in the...
Read More
Immunotherapy-Based Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
1. The complete response rates (pathological and clinical) were similar (~55%) in both groups. 2....
Read More
Poor sleep and elevation of liver function biomarkers may be predictive of liver cancer
1. Unhealthy sleep, as well elevations of liver enzymes and decreased levels of albumin and liver...
Read More
Subcutaneous amivantamab with lazertinib is non-inferior to intravenous administration, with fewer adverse reactions
1. Subcutaneous amivantamab combined with lazertinib was non-inferior to intravenous amivantamab...
Read More
Amivantamab and Lazertinib in Untreated EGFR-Mutated Advanced NSCLC
1. The progression-free survival between the amivantamab–lazertinib group (23.7 months) and the...
Read More
Daratumumab linked to improved progression-free survival and MRD-negativity in transplant-eligible myeloma patients
1. Daratumumab in combination with bortezomib, thalidomide, and dexamethasone (D-VTd) as induction...
Read More
Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced NSCLC
1. Patients with no biochemical or radiographic evidence of progressive disease had a median...
Read More
Osimertinib significantly improved progression-free survival in patients with unresectable stage III non-small cell lung cancer
1. Treatment with osimertinib significantly improved progression-free survival, compared to...
Read More
Neoadjuvant Immunotherapy in Mismatch Repair–Deficient Colon Cancer
1. No disease recurrences were observed during the median follow-up time of 26.2 months. 2....
Read More
Quantifying the reduction of primary breast cancer associated with exercise
1. Across a follow-up period of approximately 5 years, there was a non-linear relationship between...
Read More
Biparametric MRI Associated With Higher False Positive Rate than Prostate-Specific Antigen for Prostate Cancer Screening
1. In this decision model analysis, biparametric MRI (bpMRI) testing led to an increased rate of...
Read More
Long-term survival improved with use of tebentafusp for metastatic uveal melanoma
1. Across a median follow-up of 48.5 months, usage of tebentafusp for patients with metastatic...
Read More
Asciminib demonstrates superior efficacy for the treatment of CML in comparison to imatinib and second-generation TKIs
1. Asciminib demonstrated higher efficacy for the treatment of newly diagnosed CML than imatinib...
Read More
Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
1. The event-free survival at 12 months was 83.7% in the neoadjuvant group vs 57.2% in the...
Read More
Short-term androgen deprivation therapy does not improve survival in patients receiving postoperative radiotherapy for prostate cancer
1. There was no significant difference in metastasis-free survival between the ADT and non-ADT...
Read More
Large language models (LLMs) demonstrated higher error rates compared to humans in a clinical oncology question bank
1. A comparative evaluation tested five publicly available LLMs on 2044 oncology questions,...
Read More